Zhuhai, China, Apr.30, 2021--Kintor Pharmaceutical Limited (HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that the company has expanded geographical presence to Zhuhai, Guangdong Province (“Zhuhai office”). The Zhuhai office is located at Zhuhai International Health Port, Jinwan District, Zhuhai City. The role of the Zhuhai office is to speed up the clinical R&D, production and commercialization of biological drugs.

Group photo of the opening ceremony.

The opening ceremony of Zhuhai office was held at 10:08 am in this morning. The guests who attended the ceremony were Ms. Zhao Weiyuan, Mayor of The People's Government of Jinwan District, Zhuhai, Director of Zhuhai Economic and Technological Development Zone Working Committee; Mr. Zeng Yiming, Committee Member of Zhuhai Economic and Technological Development Zone Working Committee of CPC, Deputy Director of Zhuhai Economic and Technological Development Zone Working committee; Ms. Li Min, Deputy Secretary of the Party Committee and Director of Zhuhai Gree Group Co., Ltd.; Mr. Long Xin, General Manager of Zhuhai Jinhang Industrial Investment Co., Ltd, etc.

Dr. Tong Youzhi, Founder, Chairman and CEO of Kintor Pharmaceutical, commented, Thanks the guests who attended our opening ceremony of Zhuhai office for your long-term support and partnership. We will speed up the research and clinical development of biological drugs and further enrich our pipeline.

Ms. Zhao Weiyuan commented, Kintor's official settling in the Zhuhai International Health Port is a great event for both the company and Jinwan District. It can drive more high-quality innovative biotechnology companies to move to Zhuhai and help Zhuhai build a highland of biomedicine in the Guangdong-Hong Kong-Macao Greater Bay Area, which is of special significance. As the territorial government, Jinwan District will render full support to Kintor in actively capitalising on the opportunities brought about by the development of the Greater Bay Area, accelerating the progress of global clinical trials and drug launching, and making greater achievements in the field of innovative drug R&D and production.

Ms. Li Min commented, Gree Group, as the third largest shareholder and strategic partner, is full of confidence and expectations for Kintor's future. Gree will perform its duties as a shareholder and fully support Kintor to develop new advantages and make breakthroughs based in Zhuhai, and Kintor could further strengthen its brand and become a leading enterprise in innovative therapies, R&D and commercialization, thus become a typical "name card" of the development of Zhuhai's biomedical industry.